TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation - Wikidata - awgldk - TriplyDB

TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation

TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation

http://www.wikidata.org/entity/Q36368029

about

Emerging Functions of RANKL in Lymphoid Tissues A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells RANK is essential for osteoclast and lymph node development Osteoimmunology: interactions of the bone and immune system A novel member of the leukocyte receptor complex regulates osteoclast differentiation Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis Cell fate decision: T-helper 1 and 2 subsets in immune responses.A review of denosumab for the treatment of osteoporosis RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor Disorders of bone remodeling Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses High expression of antioxidant proteins in dendritic cells: possible implications in atherosclerosis.Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice.Thymic homing of activated CD4+ T cells induces degeneration of the thymic epithelium through excessive RANK signaling.Immunomodulation by blockade of the TRANCE co-stimulatory pathway in murine allogeneic islet transplantation.Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.Marrow-derived CD40-positive cells are required for mice to clear Cryptosporidium parvum infection.Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.A novel helper role for CD4 T cells Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw.Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity.Role of RANKL and RANK in bone loss and arthritis.T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion.Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis.Osteoclasts: New Insights Clinical development of anti-RANKL therapy Neonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells.CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes.TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo RANKL-RANK interaction in immune regulatory systems.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

P2860

Q21131222-FEE0686D-53DC-4A7E-BFC3-AC01AD31119F Q24291798-FCAD9591-1B2F-4802-AA87-91D7B8C37A9B Q24598872-EF8328D9-94B9-4745-BBCA-0BB352C6E5B5 Q24655113-F402D702-EF5C-4C9D-BCC2-6857004CDAC9 Q24675157-470EA0DB-FF93-45ED-85A1-C983B300D8FB Q24805600-BE911421-52C3-49CE-AEB6-A7692F0D5DAC Q24806926-B74E3B6E-8B37-47DC-8F06-1E0751255082 Q27005894-71422557-8152-41CE-894D-83C164652635 Q27674275-8FD761B2-76E8-46EE-8470-8766CA83E802 Q28295303-034A4D4A-1D69-4BB5-BA92-2EE05B2344DF Q28727655-32EFCFB8-5512-484B-BB57-81185C467BDC Q29397534-7743AB4C-DE87-43D9-8519-76378A5B5302 Q30433070-6F54CDE8-5DF9-413D-87CA-8FECF52789A3 Q33232238-4A3F7E62-F11D-4787-BE57-88EAA144CA7A Q33713257-6A004521-D782-431D-9568-E30949F86C8C Q33729251-C97016A9-E2F2-414F-9B22-9F600ABE1621 Q33805719-9A5796CF-0BF6-404B-9B41-4E3325EB77AD Q33850510-CC916E14-A777-4BFD-B139-9E7E0BFA3E30 Q33862741-3B44D0DD-DA92-44A2-AEDF-BB82E4846601 Q34006404-72CAFC75-48CE-4B73-8A29-10E457317B7F Q34086847-F18A7550-7FDF-46C6-919D-C315E7BF654C Q34087699-71AAB5DE-BE74-4531-9C5E-805486155FCA Q34090842-1D67683C-749D-4C00-8E6C-269E51E5B213 Q34111806-3A57D056-894D-4D93-BA8C-844D7696E570 Q34162783-3401E571-81CD-44A3-A4CA-30E939B351B1 Q34201118-F1926AD6-6F7C-4EC9-8126-E0F1F5FC3C99 Q34545263-74CCA405-88DC-47FA-9F80-0C9749998AA3 Q34786965-2F0069C0-8CD6-4321-A963-5430789FB573 Q34963016-EB9C9579-8FF8-4656-AAF1-648DAC0A4DC7 Q35179608-B6A8CB2B-55FF-4317-BA1B-BDDDE83AC7A1 Q35643989-7166167C-5DBF-4633-B6B2-B48590D6397F Q35664993-A9B5E5BD-D20C-4CD3-B9B0-7B4319AEED65 Q35750515-1BCC4E52-295B-4C98-8AE9-D14A849622E7 Q35755039-D1F0E415-FE53-4DDF-AC2D-BF2C6197C563 Q35901092-5ACC332E-2B6C-4250-BAA8-2A0AE8AD598D Q36375728-3254DB8C-F5B7-47E2-960D-BA4648853AB9 Q36375919-C722E538-33EC-4D6A-A8F4-4A043A89DDA7 Q36375923-D8807F0D-5929-4A45-B5E0-B514325D2311 Q36412789-DEC48AE0-8F5E-4F5C-BC5D-5FE28A09F4F1 Q36860987-4D279349-62F7-40E6-AB29-2F71467C72D6

P2860

TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation

http://www.wikidata.org/entity/Q36368029

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

TRANCE, a tumor necrosis facto ...... ndent T helper cell activation

@ast

TRANCE, a tumor necrosis facto ...... ndent T helper cell activation

@en

type

label

TRANCE, a tumor necrosis facto ...... ndent T helper cell activation

@ast

TRANCE, a tumor necrosis facto ...... ndent T helper cell activation

@en

prefLabel

TRANCE, a tumor necrosis facto ...... ndent T helper cell activation

@ast

TRANCE, a tumor necrosis facto ...... ndent T helper cell activation

@en

P1433

Q36368029-843E10B3-B5F6-48D8-A98D-0F8C90B0F3E4

P1476

Q36368029-10A699A7-CEF5-4192-81FA-A0A62A5BF365

P2093

Q36368029-16F90604-0FC8-47B2-9E88-0FF8978F4FB4

Q36368029-52B38B26-E333-4FFC-9589-ABE51CC0C1A7

Q36368029-A98AB89D-52A0-447A-814F-C543A8B0AF41

Q36368029-C37824EE-4F8B-4180-ABB4-6CAD87119C56

Q36368029-D71182FF-33EC-4EE7-A03C-4407B1E131E0

P2860

Q36368029-158FEB85-C43A-485E-998F-B5DE0F16D7AC

Q36368029-1A774DCC-046C-4867-8CCC-8F104975CBF2

Q36368029-1BDCB18D-D54A-4717-8D5F-11DA954B653E

Q36368029-2E888B22-229B-48C5-970E-15C23FEA0F86

Q36368029-304CC3FF-5194-4EFC-8C6D-196D92B017DB

Q36368029-329520D9-5D4F-433E-97FE-35AB005BEAAE

Q36368029-35283EDC-6105-4E1E-B9EB-2BD8134B4367

Q36368029-3538C15F-FE83-42F6-8676-509753BF6858

Q36368029-3D446385-B84F-4B78-8F21-C3DD357A7040

Q36368029-3DF571C6-AA09-409D-81FB-2258E038AE64

P304

Q36368029-EC2AD3D2-BA84-4676-A04F-7C5A70FE3017

P31

Q36368029-6F48BCE9-1538-43FB-A592-9F007BAFF540

P356

Q36368029-EE59E58B-04CD-4913-B2FE-F2C8EF102274

P407

Q36368029-FF288271-5681-432C-9C45-A09BE3136179

P433

Q36368029-F02E4515-643F-491B-BB53-F40CAC474B99

P478

Q36368029-B25F797A-DA68-44DE-8D61-7058A5FA6EA7

P50

Q36368029-4DA411F7-4266-41DA-B99F-181EB15CE341

P577

Q36368029-B6FA6213-CFB8-4E4D-9E7E-BDDECA8936A3

P5875

Q36368029-FE83E321-46E8-44CF-819B-8D607BDDD7C8

P698

Q36368029-4B6B7B4B-3173-4620-9A49-37BF8A5A024F

P932

Q36368029-47DADCCF-9F99-4595-91F9-E60434447E4F

P356

P1433

Journal of Experimental Medicine

P1476

TRANCE, a tumor necrosis facto ...... ndent T helper cell activation

@en

P2093

A Oxenius

http://www.w3.org/2001/XMLSchema#string

B R Wong

http://www.w3.org/2001/XMLSchema#string

M F Bachmann

http://www.w3.org/2001/XMLSchema#string

R M Steinman

http://www.w3.org/2001/XMLSchema#string

Y Choi

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

Dendritic cells and the control of immunity

The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation

Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand.

CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection.

Immunodeficiency with hyper-IgM (HIM).

P304

1025-1031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.189.7.1025

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

189

http://www.w3.org/2001/XMLSchema#string

P50

P577

1999-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13107056

http://www.w3.org/2001/XMLSchema#string

P698

10190893

http://www.w3.org/2001/XMLSchema#string

P932

2193017

http://www.w3.org/2001/XMLSchema#string